Up to 30% of all patients who are treated with a coronary stent do not respond sufficiently to
antiplatelet therapy. This condition results in an increased risk for thrombotic complications …

Background: Inhibition of platelet aggregation by clopidogrel may be insufficient in up to
30% of users. These nonresponders carry an increased risk of cardiovascular events. We …

A common functional variant in paraoxonase 1 (PON1), Q192R, was recently reported to be
a major determinant of clopidogrel response. This variant was genotyped in 566 participants …

The thienopyridine P2Y 12 receptor antagonists clopidogrel and prasugrel prevent arterial
thrombosis and are routinely used following percutaneous coronary intervention. However …

The efficacy with aspirin and clopidogrel treatment has been demonstrated in various
clinical trials. Laboratory evaluation of platelet response in recent studies revealed that a …

The widespread use of clopidogrel alone or in combination with aspirin has significantly
benefited patients with acute coronary syndrome who are managed medically or by …

Many patients experience recurrent ischemic events despite optimal antiplatelet therapy.
This has generated much interest in finding a laboratory test of platelet function to identify …

OBJECTIVES: We have prospectively investigated the association between aspirin and
clopidogrel responses and the clinical predictors of non response. METHODS: 635 Non ST …

目的观察替格瑞洛在老年急性ST 段抬高型心肌梗死(ST-segment elevated myocardial
infarction, STEMI) 患者急诊经皮冠状动脉介入治疗术(percutaneous coronary artery …

Purpose Bioavailability of clopidogrel in the form of crushed tablets administered via
nasogastric tube (NGT) has not been established in patients after cardiopulmonary …